<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351091</url>
  </required_header>
  <id_info>
    <org_study_id>HMR4003B_2501</org_study_id>
    <nct_id>NCT00351091</nct_id>
  </id_info>
  <brief_title>Risedronate in Postmenopausal Women With Low Bone Density</brief_title>
  <official_title>a Six Month, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group Study to Estimate the Pharmacodynamic Response of Two Risedronate Regimens Compared With 5mg Daily : 150mg Monthly Dose for Six Months and 15mg Daily for Thirty Days Followed by 150mg Monthly Dose for 5 Months in Postmenopausal Women With Low Bone Density.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective of this pilot study is to estimate the percent change from baseline at&#xD;
      Week 4, Month 6 in NTX bone turnover marker for a monthly 150mg dose of risedronate&#xD;
      administered for 6 months and a loading dose regimen of risedronate over a 6 month treatment&#xD;
      period both compared to a 5 mg daily dose of risedronate for 6 months&#xD;
&#xD;
      The secondary objectives are :&#xD;
&#xD;
        -  To estimate the percent change from baseline at specified visits other than Week 4,&#xD;
           Month 6 in NTX for the monthly 150 mg dose of risedronate administered for 6 months and&#xD;
           the loading dose regimen of risedronate over a 6 month treatment period both compared to&#xD;
           the 5 mg daily dose of risedronate.&#xD;
&#xD;
        -  To estimate the percent change from baseline at all specified visits in serum CTX and&#xD;
           bone specific alkaline phosphatase for the monthly 150 mg dose of risedronate&#xD;
           administered for 6 months and the loading dose regimen of risedronate over a 6 month&#xD;
           treatment period both compared to the 5 mg daily of risedronate.&#xD;
&#xD;
        -  To estimate the percent change from baseline at Month 6 in lumbar spine BMD for the&#xD;
           monthly 150 mg dose of risedronate administered for 6 months and the loading dose&#xD;
           regimen of risedronate over a 6 month treatment period both compared to the 5 mg daily&#xD;
           dose of risedronate.&#xD;
&#xD;
        -  To evaluate the safety of the risedronate 150 mg monthly and the loading dose regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine NTX at week 4 of month 6</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine NTX at other visits, serum CTX and bone specific alkaline phosphatase, lumbar spine BMD</measure>
  </secondary_outcome>
  <enrollment type="Actual">150</enrollment>
  <condition>OSTEOPOROSIS, POSTMENOPAUSAL</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RISEDRONATE</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ambulatory women,postmenopausal &gt;= 5 years&#xD;
&#xD;
          -  have lumbar spine baseline BMD within the following criterion :&#xD;
&#xD;
               -  Hologic: &lt;= 0.827 g/cm2 or&#xD;
&#xD;
               -  Lunar: &lt;= 0.942 g/cm2 or&#xD;
&#xD;
               -  Norland: &lt;= 0.768 g/cm2&#xD;
&#xD;
          -  be in general good health as determined by medical history, physical examination and&#xD;
             laboratory tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  serum 25-OH vitamin D level &lt;= 12 ng/ml&#xD;
&#xD;
          -  history of osteomalacia&#xD;
&#xD;
          -  history of active hyperparathyroidism or hyperthyroidism&#xD;
&#xD;
          -  hypocalcemia or hypercalcemia from any cause&#xD;
&#xD;
          -  depot injection &gt;10,000 IU Vitamin D in the past 9 months prior to starting the&#xD;
             investigational product&#xD;
&#xD;
          -  use of Vitamin D supplementation within 3 months prior to starting the investigational&#xD;
             product&#xD;
&#xD;
          -  use of any of the following medications within a specified number of months prior to&#xD;
             starting the investigational product :&#xD;
&#xD;
               -  any bisphosphonate.&#xD;
&#xD;
               -  use of any fluoride with the exception of fluoride use for oral hygiene&#xD;
&#xD;
               -  strontium&#xD;
&#xD;
               -  other bone active agents&#xD;
&#xD;
               -  subcutaneous estrogen implant&#xD;
&#xD;
               -  oral or parenteral glucocorticoids&#xD;
&#xD;
               -  anabolic steroids&#xD;
&#xD;
               -  estrogen or estrogen-related drugs, except for low dose vaginal creams&#xD;
&#xD;
               -  progestogen&#xD;
&#xD;
               -  calcitonin, calcitriol, or calcifediol&#xD;
&#xD;
          -  any allergic or abnormal reaction to bisphosphonates&#xD;
&#xD;
          -  creatinine clearance &lt; 30 ml/min&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>July 11, 2006</study_first_submitted>
  <study_first_submitted_qc>July 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2006</study_first_posted>
  <last_update_submitted>February 15, 2012</last_update_submitted>
  <last_update_submitted_qc>February 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

